Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $78.00.
VERA has been the topic of several research analyst reports. The Goldman Sachs Group reissued a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 target price on shares of Vera Therapeutics in a research report on Tuesday, June 2nd.
Get Our Latest Report on Vera Therapeutics
Vera Therapeutics Trading Up 6.4%
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the business earned ($0.81) EPS. On average, equities research analysts predict that Vera Therapeutics will post -6.23 EPS for the current year.
Insider Activity at Vera Therapeutics
In other news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $37.93, for a total transaction of $701,705.00. Following the completion of the sale, the chief executive officer owned 198,244 shares in the company, valued at $7,519,394.92. The trade was a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 59,951 shares of company stock worth $2,392,387 in the last ninety days. Insiders own 15.90% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. UBS Group AG boosted its stake in Vera Therapeutics by 27.9% during the 4th quarter. UBS Group AG now owns 207,289 shares of the company’s stock valued at $10,497,000 after purchasing an additional 45,214 shares during the last quarter. Hudson Bay Capital Management LP raised its stake in shares of Vera Therapeutics by 47.4% in the third quarter. Hudson Bay Capital Management LP now owns 440,591 shares of the company’s stock worth $12,804,000 after purchasing an additional 141,615 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Vera Therapeutics by 11.9% in the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after purchasing an additional 379,748 shares in the last quarter. Schroder Investment Management Group boosted its position in shares of Vera Therapeutics by 82.4% during the third quarter. Schroder Investment Management Group now owns 679,992 shares of the company’s stock valued at $19,652,000 after buying an additional 307,243 shares during the last quarter. Finally, Braidwell LP bought a new stake in Vera Therapeutics during the third quarter worth $13,738,000. Institutional investors and hedge funds own 99.21% of the company’s stock.
Vera Therapeutics Company Profile
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Featured Articles
- Five stocks we like better than Vera Therapeutics
- Abivax: Wall Street Catches Up to the Data
- AI Insider Activity: Are Sales Across 3 Key Stocks Noteworthy or Just Noise?
- 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers
- Top 135 Best Locally Owned BBQ Supply Stores in the U.S., According to Survey [2026]
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
